share_log

CRISPR Therapeutics Shares Are Trading Higher After the Company and Vertex Pharmaceuticals Announced the FDA Granted Exagamglogene Autotemcel a Rolling Review for the Potential Treatment of Sickle Cell Disease and Transfusion-dependent Beta Thalassemia.

CRISPR Therapeutics Shares Are Trading Higher After the Company and Vertex Pharmaceuticals Announced the FDA Granted Exagamglogene Autotemcel a Rolling Review for the Potential Treatment of Sickle Cell Disease and Transfusion-dependent Beta Thalassemia.

CRISPR治疗公司的股价上涨,此前该公司和Vertex制药公司宣布,FDA授予Exagamlogene Autotemcel对镰状细胞疾病和输血依赖的贝塔地中海贫血的潜在治疗进行滚动审查。
Benzinga ·  2022/09/27 11:16

CRISPR Therapeutics shares are trading higher after the company and Vertex Pharmaceuticals announced the FDA granted exagamglogene autotemcel a rolling review for the potential treatment of sickle cell disease and transfusion-dependent beta thalassemia.

CRISPR治疗公司的股价上涨,此前该公司和Vertex制药公司宣布,FDA批准exagamlogene Autotemcel对镰状细胞疾病和输血依赖的β地中海贫血的潜在治疗进行滚动审查。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发